Concepedia

Outcomes of <i>TP53</i>‐mutant acute myeloid leukemia with decitabine and venetoclax

Kunhwa Kim, Abhishek Maiti, Sanam Loghavi, Rasoul Pourebrahim, Tapan M. Kadia, Caitlin R. Rausch, Ken Furudate, Naval Daver, Yesid Alvarado, Maro Ohanian,

Cancer · 2021 · 149 citations · 18 references

DOIFull text

Open access

Abstract

Patients with TP53<sup>mut</sup> AML have lower response rates and shorter survival with DEC10-VEN.

References

18

Genomic Classification and Prognosis in Acute Myeloid Leukemia

Elli Papaemmanuil, Moritz Gerstung, Lars Bullinger et al. · New England Journal of Medicine · 2016 · 4.2K citations · Full text

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

Courtney D. DiNardo, Brian A. Jonas, Vinod Pullarkat et al. · New England Journal of Medicine · 2020 · 2.6K citations · Full text

<i>TP53</i> and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes

John S. Welch, Allegra A. Petti, Christopher A. Miller et al. · New England Journal of Medicine · 2016 · 774 citations · Full text

Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study

Courtney D. DiNardo, Keith W. Pratz, Anthony Letai et al. · The Lancet Oncology · 2018 · 692 citations

, , +10

Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML

Courtney D. DiNardo, Ing Soo Tiong, Anna Quaglieri et al. · Blood · 2020 · 628 citations · Full text